[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hpv-related-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hpv-related-disease":58},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100370084",false,"NCT04098744","Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2\u002F3)","A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Vaginal Inserts for the Treatment of Patients With Cervical Intraepithelial Neoplasia (CIN2\u002F3)","ART-CIN_IIB","Inclusion Criteria:\n\n* Adult females age ≥ 25 years\n* Capable of informed consent\n* Any HPV genotype detectable by DNA test\u002FHPV genotyping\n* Colposcopically-directed, histologically confirmed tissue diagnosis of cervical high grade squamous intraepithelial lesions (CIN2, CIN3, or CIN2\u002F3)\n* Women of childbearing potential agree to use birth control through week17 of the study.\n* Weight ≥ 50kg\n\nExclusion Criteria:\n\n* Pregnant and nursing women\n* Active autoimmune disease\n* Taking immunosuppressive medication\n* HIV seropositivity\n* Immunocompromised subjects\n* Evidence of concurrent cervical adenocarcinoma in situ\n* Concurrent malignancy except for nonmelanoma skin lesions, because treatment for other cancers have systemic effects","FEMALE","25 Years","100 Years",{"count":20,"type":21},78,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2\u002F3).",[27,28,29,30,31],"CIN 2\u002F3","HPV Infection","Pre-Cancerous Dysplasia","Cervical Dysplasia","HPV Related Disease",[33,34,35,36,37,38,39,40,41,42,43,44],"treatment study","cancer prevention","non-surgical","HPV related disease","CIN","topical treatment","vaginal inserts","artesunate","artemisinin","non-invasive","high risk HPV","vaginal suppository","RECRUITING","2025-09-29",{"date":48,"type":49},"2025-10-02","ACTUAL",{"date":51,"type":49},"2020-09-09",{"date":53,"type":21},"2026-12-31",{"name":55,"class":56},"Frantz Viral Therapeutics, LLC","INDUSTRY",7,""]